

Santen Pharmaceutical Co., Ltd. Investor Meeting Financial Results for the 1st Half of FY2011; Financial Forecast for the FY2011;

November 2, 2011 Akira Kurokawa President & CEO



Financial Results for the 1st Half FY2011

S Financial Highlights for 1st Half FY2011

	FY2010 1st Half Actual	FY2011 1st Half Actual	Var. %	FY2011 1st Half Forecast*	Achieve- ment %
Net Sales	53.91	56.78	+5.3%	57.30	99.1%
Operating Income	14.11	14.57	+3.2%	14.50	100.5%
Ordinary Income	14.49	15.05	+3.9%	14.80	101.7%
Net Income	9.27	9.90	+6.8%	10.00	99.1%

Summary of 1st Half FY2011

Sales

Steady growth of 5.3% from the same period last year.

Japan sales was driven mainly by steady growth in glaucoma and dry-eye segments.

Overseas sales maintained steady growth, both in Asia and Europe.

Operating Income

- Operating expense excluding R&D costs increased due to increased HR costs related to strengthening of overseas sales platforms.
- Maintained thorough R&D related investments.
- Despite the increased spending, total operating expense level was controlled within the budget.

1st Half FY2011 Net Sales: Variances (vs. 1st Half FY2010)

FY2010 1st Half Net Sales (Actual) ¥53.91billion

> +¥2.87 billion

FY2011 1st Half Net Sales (Actual) ¥56.78billion

Japan: +1.78billion

- Prescription Ophthalmics
- Anti-rheumatics
- OTC Drugs
- Medical Devices
- Others

halmics
+¥1.26billion
+¥0.08billion
-¥0.06billion
+¥0.24billion
+¥0.25billion

Overseas + ¥1.08billion

- Europe
 (Forex impact)
- Asia
- (- China
- (Forex impact:
- Korea (Forex impact:

+¥0.30billion -¥0.08billion) +¥0.40billion +¥0.00billion) +¥0.38billion +¥0.09billion

- -¥0.13billion)
- +¥0.25billion -¥0.01billion)

Prescription Ophthalmics (Japan)

◆Anti-infective	-¥0.41billion		
Cornea (Dry Eye)	+¥1.38billion		
Diquas	+¥1.12billion		
Glaucoma	+¥1.23billion		
Tapros:	+¥0.26billion		
Cosopt:	+¥1.82billion		
Anti-allergy	+¥0.06billion		
Others	-¥1.00billion		

rn	no
	DE

Prescription Ophthalmics						
+¥0.52billior						
C- Western Europe	+¥0.06billion					
- Eastern Europe	+¥0.21billion					
- Northern Europe	+¥0.13billion					
- Russia	+¥0.10billion					

<currency rates=""></currency>					
<u> </u>	Y10.Q2 actual	FY11.Q2 actual			
US\$	JPY 88.88	JPY 79.74			
Euro	JPY 115.85	JPY 116.08			
CNY	JPY 13.40	JPY 12.51			

1st Half FY2010 Net Sales: Variances (vs. 1st Half FY2011 Forecast)

FY2011 1st Half Net Sales (Forecast*) ¥57.30billion

-¥0.51billion

FY2011 1st Half Net Sales (Actual) ¥56.78billion

Japan: -¥0.63billion

- **Prescription Ophthalmics**
- Anti-rheumatics
- \$
- **OTC** Drugs \oplus
- **Medical Devices +**
- Others \$

-¥0.67billion
-¥0.01billion
+¥0.00billion
+¥0.01billion
+¥0.04billion

Overseas: + ¥0.12billion

- **⊕** U.S. (Forex impact
- Europe (Forex impact
- Asia
- China
- (Forex impact:
- Korea
- (Forex impact:

- -¥0.08billion -¥0.01bill
- +¥0.08bil +¥0.11billion)
 - +¥0.12billion
- -¥0.
- -¥0.00billion)

- +¥0.14billion
- -¥0.00billion)

03bil	lion	\ -
	:	_

lion)	Prescrip			
llion				
lion)				

-¥0.35billion Cornea (Dry Eye) Diquas -¥0.23billion Glaucoma +¥0.22billion Tapros:

Prescription Ophthalmics

(Japan)

- Cosopt:
- Anti-allergy

Anti-infective

Others

-¥0.38billion +¥0.29billion

-¥0.14billion

-¥0.24billion

- -¥0.15billion
- Europe
- ption Ophthalmics

+¥0.07billion

- Western Europe -¥0.01billion
- Eastern Europe
- Northern Europe
- Russia

+¥0.13billion +¥0.03billion

-¥0.08billion

<curre< th=""><th>ency Rates></th><th></th></curre<>	ency Rates>	
<u>F</u> `	Y11 Forecast	FY11.Q2 Actual
US\$	JPY 82.00	JPY 79.74
Euro	JPY113.00	JPY 116.08
CNY	JPY 12.50	JPY 12.51
	<u>F</u> ` US\$ Euro	Euro JPY113.00

*Forecast as of: May 10, 2011

S Changes in Income Statement

(JPY billions)	FY2010 1 st Half	FY2011 1 st Half			
	Actual	Actual	Variance	Major Changes	
Net Sales	53.91	56.78	+2.87		
Cost of Sales (% of net sales)	17.43 32.3%	17.76 31.3%	+0.33 -1.0pt	Decrease in fixed cost -0.1pt, change in product mix -0.5pt, decrease in license related income -0.2pt, others -0.2pt	
SGA excluding R&D (% of net sales)	15.98 29.7%	16.84 29.7%	+0.86 +0.0pt	•Japanese sales expense : -¥0.29bil •Overseas expenses : Europe +¥0.62bil, Asia +¥0.40bil (Forex impact -¥0.10bil)	
R&D Expenses (% of net sales)	6.37 11.8%	7.60 13.4%	+1.22 +1.5pt		
Operating Profit (% of net sales)	14.11 26.2%	14.57 25.7%	+0.45 -0.5pt		
Non-operating Income Non-operating Expense	0.48 0.10	0.50 0.02	+0.02 -0.08		
Ordinary Income	14.49	15.05	+0.55		
Extraordinary Gain Extraordinary Loss	0.00 0.11	0.06 0.02	+0.05 -0.09	<pre><currency rates=""> FY10.Q2 actual FY11.Q2 actual</currency></pre>	
Net Income before Tax	14.38	15.08	+0.70	US\$ JPY 88.88 JPY 79.74 Euro JPY115.85 JPY 116.08	
Corporate Tax	5.11	5.18	+0.07	CNY JPY 13.40 JPY 12.51	
Net Profit	9.27	9.90	+0.63		

Summery of Change in Balance Sheet

	FY 2010		FY2011 1 st Half		
(JPY billions)	Actual	% of Total	Actual	% of Total	Var.
Current Asset	137.66	74.5%	142.28	75.5%	+4.61
Fixed Asset	47.13	25.5%	46.17	24.5%	-0.95
Deferred Asset	-	-	-	-	-
Total Asset	184.80	100.0%	188.45	100.0%	+3.65
Current Liabilities	24.10	13.0%	22.29	11.8%	-1.81
Non-current Liabilities	4.29	2.3%	4.00	2.1%	-0.28
Total Liabilities	28.39	15.4%	26.30	14.0%	-2.09
Total Net Asset	156.40	84.6%	162.15	86.0%	+5.75
Total Liabilities Net Assets	184.80	100.0%	188.45	100.0%	+3.65

Major Changes

Current Asset:	Cash and deposits +¥4.43bil, Merchandise and finished products +¥1.01bil, Raw materials -¥0.31bil
Fixed Asset :	Buildings and structures -¥0.49bil, Construction in progress +¥0.41bil, Software -¥0.21bil Investment securities -¥0.35bil, LT deferred tax assets -¥0.45bil
Current Liabilities:	Accounts payable -¥0.71bil, Unpaid billings -¥0.79bil, Income tax payable +¥0.57bil, Provision for bonus -¥0.11bil
Fixed Liabilities :	Provisions for employees' retirement fund +¥0.12bil, Provisions for directors' retirement fund -¥0.26bil
■Net asset :	Retained earnings +5.55bil, Other securities revaluation profit +¥0.35bil, Foreign currency translation adjustments -¥0.31bil



Financial Forecast for the FY2011

S Financial Forecast for FY2011

(JPY billions)	FY2010 Actual	FY2011 Forecast	Var. %
Net Sales	110.81	116.00	+4.7%
Operating Income	30.73	30.00	-2.4%
Ordinary Income	31.48	30.50	-3.1%
Net Income	21.33	20.50	-3.9%

ROE	14.5%	12.6%	-1.9pt
-----	-------	-------	--------

*Forecast as of: May 10, 2011

Sales/Income Outlook for the FY2011

(IDV billions)	FY2010	FY2	011
(JPY billions)	Actual	Forecast	Var.
Net Sales	110.81	116.00	+5.18
Cost of Sales	34.43	36.00	+1.56
(% of net sales)	31.1%	31.0 %	-0.0 pt
SG&A excluding R&D	32.41	34.00	+1.58
(% of net sales)	29.3 %	29.3 %	+0.1 pt
R&D Expense	13.22	16.00	+2.77
(% of net sales)	11.9 %	13.8 %	+1.9 pt
Operating Income	30.73	30.00	-0.73
(% of net sales)	27.7 %	25.9%	- 1.9 pt
Non-operating Income/Loss	0.74	0.50	-0.24
Ordinary Income	31.48	30.50	- 0.98
Extraordinary Income/Loss	- 0.40	0.00	+0.40
Net Income before Tax	31.07	30.50	- 0.57
Income Taxes	9.74	10.00	+0.25
Net Income	21.33	20.50	- 0.83
ROE	14.5 %	12.6%	- 1.9 pt

<Currency rate> <u>FY2010 actual</u> US\$ ¥85.57 Euro ¥113.45 CNY ¥12.94 <u>FY2011 forecast</u> US\$ ¥82.00 Euro ¥113.00 CNY ¥12.50



References



Reference: Financial Results for the 1st Half FY2011

S Net Sales by Business Segment

(J	IPY billions)	FY2011 1 st Half Actual					
		Jap	an	Overseas		Total	
		Sales	Var.	Sales	Var.	Sales	Var.
Pł	harmaceuticals	46.77	+3.4%	8.44	+9.3%	55.22	+4.3%
	Prescription Pharmaceuticals	44.33	+3.8%	8.44	+9.3%	52.77	+4.6%
	Ophthalmic	38.68	+3.4%	8.24	+10.5%	46.93	+4.6%
	Anti-RA	5.07	+1.7%	0.08	+45.5%	5.15	+2.2%
	Others	0.57	+78.6%	0.10	-46.7%	0.68	+30.4%
	OTC Pharmaceuticals	2.44	-2.4%	0.00	-11.2%	2.44	-2.4%
Ot	thers	0.92	+35.9%	0.64	+136.5%	1.56	+64.6%
	Medical Devices	0.91	+36.2%	0.64	+136.5%	1.55	+65.0%
	Others	0.00	+6.1%	-	-	0.00	+6.1%
Тс	otal	47.70	+3.9%	9.08	+13.6%	56.78	+5.3%



	FY2010	FY2011 1 st Half			
(JPY billions)	1 st Half Actual	Actual	Var.	Var. %	
U.S.	0.62	0.92	+0.30	+49.0%	
Europe	4.07	4.47	+0.40	+9.9%	
Asia	3.30	3.68	+0.38	+11.7%	
Others	0.00	0.00	-0.00	-	
Total	7.99	9.08	+1.08	+13.6%	



(JPY billion	(JPY billions)		
Cash an	Cash and cash equivalents at the beginning of the year		
Net incr	6.23		
	Cash flows from operating activities	9.32	
	Cash flows from investing activities	1.41	
	Cash flows from financial activities	-4.24	
	Effect of exchange rate changes on cash and cash equivalents	-0.26	
Cash an	nd cash equivalents at the end of the year	78.71	

Note: "Cash and cash equivalents" include cash equivalents thus differ from "cash and deposits" in the Balance Sheets.

S Capital Expenditures / Depreciation & Amortization / Lease Expenses

	FY2	010	FY2011		
(JPY billions)	1st Half Actual	Full Year Actual	1st Half Actual	Full Year Forecast	
Capital Expenditures	0.49	1.70	1.26	6.21	
Depreciation and Amortization	1.37	2.80	1.31	2.95	
Lease Payments	0.12	0.15	0.01	0.04	



Reference: FY2011 Financial Forecasts

Sales Forecast by Business Segment / Overseas Sales

		FY2011 Forecast*						
(J	PY billions)	Jap	an	Over	seas	То	Total	
		Sales	Var.	Sales	Var.	Sales	Var.	
Pł	harmaceuticals	94.28	+3.6 %	19.07	+8.8 %	113.35	+4.4 %	
	Prescription Pharmaceuticals	89.64	+3.8 %	19.05	+8.8 %	108.69	+4.7 %	
	Ophthalmic	78.56	+3.9 %	16.31	+7.3 %	94.88	+4.5 %	
	Anti-RA	9.91	+1.9 %	0.10	-3.5 %	10.01	+1.8 %	
	Others	1.16	+13.9 %	2.63	+19.9%	3.80	+18.0 %	
	OTC Pharmaceuticals	4.64	-1.5 %	0.01	+36.0 %	4.65	-1.4 %	
Ot	thers	1.98	+32.3 %	0.65	-10.7 %	2.64	+18.2 %	
	Medical Devices	1.97	+32.6 %	0.65	-10.7 %	2.63	+18.3 %	
	Others	0.01	-6.5 %	_	_	0.01	-6.5 %	
Тс	otal	96.27	+4.0%	19.72	+8.0 %	116.00	+4.7 %	

*Forecast as of: May 10, 2011



(JPY billions)	FY2010 Actual	F	2011 Forecas	st*
		Forecast	Var.	Var. %
U.S.	3.06	3.62	+0.55	+18.2%
Europe	8.51	9.05	+0.53	+6.3%
Asia	6.66	7.02	+0.36	+5.4%
Others	0.00	0.01	+0.00	+60.0%
Total	18.26	19.72	+1.46	+8.0%



Reference: Market Overview of Prescription Ophthalmic in Japan

S Japan: Trend & Competition in Ophthalmics (1)


• **Ophthalmology Total**: Market grew by 6.1% in the first half of FY11. Retinal segment and anti-allergy segment continued to lead the market growth. Santen's market share was 36.7%

• Glaucoma:

Market grew by 1.8% in the first half of FY11. Santen's sales grew by 15.0%. Santen held 28.0% share of the glaucoma market by the contribution of Tapros and Cosopt.

• Corneal:

Market grew by 11.0% in the first half of FY11. Santen's sales grew by 14.7%, and Santen's market share increased to 77.6% with the contribution of Hyalein and Diquas.




Source: ©2011 IMS Japan IMS-JPM 2009-11 Santen analysis based on IMS data Reprinted with permission 22

-Santen:

-Glaucoma : Tapros, Cosopt, Timoptol/XE, Rescula, Detantol, etc. -Cornea / Dry Eye : Hyalein, Diguas etc.

S Japan: Trend & Competition in Ophthalmics (2)

- Anti-infection: Market in the period in the first half of FY11 shrunk by 3.6%. Santen maintained 68.3% of market share with primary contribution from Cravit.
- Anti-allergy: Market grew by 17.9% in the first half of FY11 Santen's share was 19.1%.



-Santen:

- Anti-infection: Cravit, Tarivid, etc.

- Anti-allergy: Livostin, Alegysal

Source: ©2011 IMS Japan IMS-JPM 2009-11 Santen analysis based on IMS data Reprinted with permission 23



FY2011 Second Quarter Status of Clinical Development

Toshiaki Nishihata, Ph.D.

Member of the Board Executive Corporate Officer, U.S. and Europe Business, Head of Research and Development Division

S Major Clinical Pipeline List (1) [by Disease] (Red underlined: Change from Q1 FY11 Presentation)

			,	Global Product	Product
Disease	Phase 1	Phase 2	Phase 3	NDA	Approved/ Launched
Glaucoma	DE- Adenos		DE-111 Tafluprost/Timolol EU JP		085 prost JP· <u>Asia</u> EU·Latin America
Corneal/ conjunctival		DE-101 Rivoglitazone		DE-089 Diquafosol Sodium	
disease (Dry eye)		-105 combo JP DE-110	<u>China</u>	Korea	Japan
Retinal/ Uveal		SEGRA	DE-109 Sirolimus		
disease			DE-102 tamethasone		
Other Infection, Allergy, RA		DE-098 Anti APO-1 Antibody	DE-114 Epinastine HCI		DE-108 Levofloxacin 1.5%

Japan (Asia)

Major Clinical Pipeline List (2) [by Region] (Red underlined: Change from Q1 FY11 Presentation)

Global product

Japan (Asia) Product

Region	Phase 1	Phase 2	Phase 3	NDA	Approved/ Launched
Japan			DE-102 etamethasone		DE-085 Tafluprost
		DE-090 Lomerizine HCI	DE-111 Tafluprost/Timolol		DE-089 Diquafosol Sodium
		DE-105 Peptide Combo	DE-114 Epinastine HCI		DE-108 Levofloxacin 1.5%
		DE-098 Anti APO-1 Antibody			
North America	DE-105 Peptide combo	DE-110 SEGRA	DE-109 Sirolimus		prost Latin America
(Including Latin America)		DE-101 Rivoglitazone			
		112 sine A _{2A}			
Asia					prost Korea, etc
				089 ol Sodium Korea	
Europe			DE-111 Tafluprost/Timolol		DE-085 Tafluprost

S Major Clinical Projects (DE-085)

• DE-085 (Glaucoma, Ocular hypertension)

TAPROS, TAFLOTAN in Santen areas, SAFLUTAN in Merck* areas

Pagion	Development Stage		Remarks
Region	As of November 1, 2011	As of August 2, 2011	Remarks
Japan	Launched	Launched	Generic name:
Europe**	Launched: 27 countries Approved: 39 countries Partly out-licensed to Merck*	Launched: 27 countries Approved: 37 countries Partly out-licensed to Merck*	Tafulprost Launched in:
Asia	Launched: 4 countries Approved: 6 countries NDA filed: China	Launched: 4 countries Approved: 5 countries NDA filed: China	Japan (Dec. 2008) Europe (Jun. 2008) Asia (Mar. 2010)
U.S./ Others	Out-licensed to Merck* Launched: 4 countries Approved: 10 countries NDA filed: U.S.	Out-licensed to Merck* Launched: 4 countries Approved: 9 countries NDA filed: U.S.	Latin America (Aug. 2010) Out-licensed to: Merck & Co. (Apr. 2009)

Launched: Total of 36 countries worldwide

- Santen: Japan and 4 countries in Asia (Hong Kong, Korea, Indonesia, Singapore) 20 countries in Europe (Germany, Finland and 18 other countries)

- Merck*: 7 countries in Europe (U.K., Spain, Netherlands, Italy, Portugal, Austria, Switzerland)

4 countries in Latin America (Bahamas, etc.)

Approved: Total of 56 countries worldwide

(newly added: 4 countries; Thailand, Hungary, Azerbaijan, Panama)

*Merck areas (since April 2009): Western Europe excluding Germany, North America, South America, and Africa **Including CIS



• DE-089 (Dry eye)

DIQUAS in Japan

	Development Stage		
Region	As of November 1, 2011	As of August 2, 2011 (Previous announcement)	Remarks
Japan	Launched	Launched	Generic name:
Asia	China: Preparing NDA Korea: NDA filed	China: P3 Korea: NDA filed	Diquafosol sodium

Major Clinical Projects Update - Glaucoma, Ocular hypertension -

• DE-090

Region	Development Stage		
	As of November 1, 2011	As of August 2, 2011 (Previous announcement)	Remarks
Japan	P2	P2	Generic name: Lomerizine HCI

• DE-111

	Development Stage		
Region	As of November 1, 2011	As of August 2, 2011 (Previous announcement)	Remarks
Japan	P3	P3	Generic name: Tafluprost/
Europe	P3	P3	Timolol maleate (Combination drug)

• DE-112

Region	Development Stage		
	As of November 1, 2011	As of August 2, 2011 (Previous announcement)	Remarks
U.S.	P1/2a	P1/2a	Adenosine A _{2A} receptor agonist

S Major Clinical Projects Update – Corneal disease -

•DE-101 (Corneal and conjunctival epithelial disorders associated with dry eye, etc.)

Region	Development Stage		
	As of November 1, 2011	As of August 2, 2011 (Previous announcement)	Remarks
U.S.	P2	Preparing P2	Generic name:
Japan	P2b completed	P2b completed	Rivoglitazone

•DE-105 (Persistent corneal epithelial defects)

Region	Development Stage		
	As of November 1, 2011	As of August 2, 2011 (Previous announcement)	Remarks
Japan	P2	P2	Combination of
U.S.	Preparing P2	Preparing P2	peptides

•DE-110 (Corneal and conjunctival epithelial disorders associated with dry eye, etc)

Region	Development Stage		
	As of November 1, 2011	As of August 2, 2011 (Previous announcement)	Remarks
U.S.	P2	P2	Selective glucocorticoid receptor agonist (SEGRA)

7



• **DE-102** (Diabetic macular edema)

Region	Development Stage		
	As of November 1, 2011	As of August 2, 2011 (Previous announcement)	Remarks
Japan	P2/3	P2/3	Generic name: Betamethasone

• DE-109 (Uveitis)

Region	Development Stage		
	As of November 1, 2011	As of August 2, 2011 (Previous announcement)	Remarks
U.S.	P3	P3	Generic name: Sirolimus



• DE-108 (Bacterial conjunctivitis)

	Development Stage		
Region	As of November 1, 2011	As of August 2, 2011 (Previous announcement)	Remarks
Japan	Launched (June 2011)	Launched (June 2011)	Generic name: Levofloxacin (1.5%)

• **DE-114** (Allergic conjunctivitis)

Region	Development Stage		
	As of November 1, 2011	As of August 2, 2011 (Previous announcement)	Remarks
Japan	P3	P3	Generic name: Epinastine HCI

• DE-098 (Rheumatoid arthritis)

Region	Development Stage		
	As of November 1, 2011	As of August 2, 2011 (Previous announcement)	Remarks
Japan	P2	P2	Anti-APO-1 antibody



- Information given in this announcement and accompanying documentation contains certain forward-looking statements concerning forecasts, projections and plans whose realization is subject to risk and uncertainty from a variety of sources. Actual results may differ significantly from forecasts.
- Business performance and financial condition are subject to the effects of medical regulatory changes made by the governments of Japan and other nations concerning medical insurance, drug pricing and other systems, and to fluctuations in market variables such as interest rates and foreign exchange rates.
- The process of drug research and development from discovery to final approval and sales is long, complex and uncertain. Individual compounds are subject to a multitude of uncertainties, including the termination of clinical development at various stages and the non-approval of products after a regulatory filing has been submitted. Forecasts and projections concerning new products take into account assumptions concerning the development pipelines of other companies and any co-promotion agreements, existing or planned. The success or failure of such agreements could affect business performance and financial condition significantly.
- Business performance and financial conditions could be affected significantly by a substantial drop in sales of a major drug, either currently marketed or expected to be launched, due to termination of sales as a result of factors such as patent expiry and complications, product defects or unforeseen side effects. Santen Pharmaceutical also sells numerous products under sales and/or manufacturing license from other companies. Business performance could be affected significantly by changes in the terms and conditions of agreements and/or the non-renewal of agreements.
- Santen Pharmaceutical is reliant on specific companies for supplies of certain raw materials used in production. Business performance could be affected significantly by the suspension or termination of supplies of such raw materials if such and event were to adversely affect supply capabilities for related final products.